Articles By Jack Cush, MD
Comorbidities Undermine Clinical Outcomes in Psoriatic Arthritis
Analysis of data from the DANBIO registry of psoriatic arthritis patients treated with tumor necrosis factor inhibitor therapy shows that comorbidities were associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates to TNFi.
Read Article
Severe Obesity Worsens Disability in Rheumatoid Arthritis
A study from the Veterans Affairs clinics and the National Data Bank of Rheumatic Diseases shows that rheumatoid arthritis (RA) patients who were severely obese had a greater risk of progressive disability compared to overweight patients; that was not explained by their arthritis or inflammation.
Read Article
The RheumNow Week in Review – FDA Showdown for Baricitinib (4.27.18)
Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.
Read Article
It Begins with the Introduction
The introduction of a guest or speaker should be simple, functional and respectful. In the least, it should go something like, “I have the honor of introducing our speaker, Dr. John Brown, who comes to us from Brown University, where he is the Chief of Internal Medicine. Today he’s going to lecture on “the right way to lecture”. However, no one does this. Instead most try to do more, usually with knowledge gaps, and end up delivering incomplete, awkward or bad introductions. Introductions tend to either be awkward or great.
Read Article
Fixed and Tailored Rituximab Regimens Equal in ANCA Associated Vasculitis
The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs).
Read Article
FDA Arthritis Panel Split on the Efficacy and Safety of Baricitinib in RA
On Monday, April 23rd the FDA convened the Arthritis Advisory Committee (AAC) to evaluate Lilly’s resubmitted NDA for the approval of the JAK inhibitor baricitinib for use in rheumatoid arthritis (RA).
Read Article
Will Aspirin Cotherapy Undermine Celecoxib’s Safety Effects?
The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA).
Read Article
The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.
Read Article
Tobacco Associated Deaths in the USA
JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall mortality risk, and a much highers cancer mortality risk compared to nonsmokers.
Read Article
Shared Epitope - Smoking Pathogenic Link Clarified
Proceedings of the National Academy of Sciences (PNAS) has published new research on the mechanistic link between the rheumatoid arthritis (RA) "shared epitope" (SE) risk alleles and environmental triggers such as cigarette smoke that leads to joint inflammation and bony destruction.
Read Article
